Status:
RECRUITING
National Longitudinal Cohort of Hematological Diseases (NICHE) - CART
Lead Sponsor:
Institute of Hematology & Blood Diseases Hospital, China
Conditions:
Hematological Malignancies
Eligibility:
All Genders
Brief Summary
This is a multicenter, ambispective, longitudinal, observational cohort study investigating CAR-T cell therapy in Chinese patients with hematological malignancies. A consortium of Phase IV clinical tr...
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- Patients with clinically diagnosed hematologic malignancies
- Patients treated with CAR-T cell therapy
- Signed the informed consent form
Exclusion
Key Trial Info
Start Date :
June 1 2021
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2032
Estimated Enrollment :
1000 Patients enrolled
Trial Details
Trial ID
NCT06607289
Start Date
June 1 2021
End Date
December 31 2032
Last Update
June 17 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Institute of Hematology & Blood Diseases Hospital
Tianjin, Tianjin Municipality, China, 300000